Cost per true positive detected for the intervention strategy of the Micral-Test followed by calibration of positives with the radioimmunoassay test was Lit. 76,183. Cost per true positive of the gold standard radioimmunoassay test was Lit. 100,295. The authors calculated that given the same budget for screening using the Micral-Test followed by the radioimmunoassay test for positive results made it possible to screen 51% more of the population. A one-way sensitivity analysis which varied the prevalence of albuminuria showed that the semi-quantitative Micral-Test as a first-line screen was more cost-effective at lower prevalence. The two screening strategies however converged at a higher prevalence of approximately 60%, when the detection cost of a true positive was equivalent with both strategies.